If you’re hunting for speculative stocks, each with the potential for remarkable returns of up to 3X, then this article is your compass. But remember, the greater the potential reward, the higher the inherent risk. Think of it like a game-winning three-pointer – the stakes are high, but then so is the glory.
And let’s face it, in investing as in basketball, three-pointers are attention-grabbers. They demand skill, vision, and a touch of daring – because hey, no one ever got excited about a layup. While the latter might be more of a sure thing, it’s the three-pointers that get the cheers, and it’s no different for the stocks we’re looking at today.
So, if you’re feeling brash, let’s dive into three riveting stock picks with the kind of upside potential that could make your portfolio do a victory dance.
US Gold (USAU)
Source: Misunseo / Shutterstock.com
Drawing inspiration from the gold-rich terrains of Elko, Nevada, US Gold (NASDAQ:USAU) combs through the earth for precious morsels. In the world of metal and mining, it might not be the biggest name, but experts like H.C. Wainwright’s Heiko Ihle see the potential for USAU to hit $11 – a jaw-dropping 220% upside. And if that prospect excites you, hold on to your hat, because last year, Alliance Global Partners projected a staggering $18-a-share price, which would deliver a mind-blowing 423% in returns.
However, before you hop on board, there are storm clouds on the horizon. Since the beginning of this year, USAU has taken a 19% tumble. Plus, according to GuruFocus, the company has yet to ring any cash registers since fiscal year 2017. Now, as an exploration and development specialist, a dry sales spell isn’t necessarily alarming, but it’s certainly worth noting.
But if the fear of missing out is creeping up, take heart. US Gold stands to benefit from two solid trends – a sticky inflation picture and the burgeoning demand for precious metals in the EV industry. So, despite the gloom, this little-known entity could still knock it out of the park.
Aeva Technologies (AEVA)
Source: T. Schneider / Shutterstock.com
Hailing from the world of high-tech, Aeva Technologies (NYSE:AEVA) is the brainchild behind next-gen sensing and perception systems. Through its innovative 4D lidar sensors, it anticipates trajectories and ranges concurrently – a game-changer for the autonomy industry. Picture a wide receiver in American football, not just catching the ball but also plotting its course as it sails through the air. AEVA’s technology is doing exactly that – anticipating the path ahead.
Experts feel the potential, too, with a consensus pick of $3.50 on the target – a hefty 230% possible return. The most optimistic estimate even lands at $5. Yet, AEVA stumbled over the past year, losing 37% of its value, leaving investors skeptical. But it’s on an upswing since January, which makes AEVA a speculative but compelling play for those who believe in its vision.
Stoke Therapeutics (STOK)
Source: Mongkolchon Akesin / Shutterstock.com
Stepping into the world of biotech, Stoke Therapeutics (NASAQ:STOK) is like a codebreaker, unraveling the mysteries of severe diseases through RNA-based medicines. But despite its pioneering work, STOK hasn’t enjoyed the warmest reception from investors. With a stumble of almost 10% at the start of the year and a 40% retreat over the past 52 weeks, it’s been an uphill climb.
However, analysts are standing by the company, pitching a $19.17 target and an eye-popping 264% potential return. Interestingly, STOK also bears a significant short interest, which could signify a tussle between believers and naysayers, adding an extra layer of intrigue to this already compelling stock.
So, for intrepid investors who are ready to ride the rollercoaster of biotech stocks, STOK could be a riveting play with stakes as high as the potential rewards.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
